Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $64M | $11M | $8M | $11M | 17.4% | 17.0% | 46.3% |
| 2024 | $55M | $7M | $5M | $9M | 11.6% | 13.8% | 62.7% |
| 2023 | $48M | $5M | $3M | $-0M | 8.4% | 15.4% | 37.4% |
| 2022 | $42M | $4M | $2M | $-2M | 6.7% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 41.66 | 48.07 | 54.72 | 64 |
| Operating Revenue | - | 41.66 | 48.07 | 54.72 | 64 |
| Cost Of Revenue | - | 10.22 | 11.55 | 12.99 | 14.03 |
| Gross Profit | - | 31.44 | 36.52 | 41.73 | 49.97 |
| Operating Expense | - | 28.47 | 32.51 | 35.15 | 40.31 |
| Research And Development | - | 1.36 | 0.92 | 0.66 | 1 |
| Selling General And Administration | - | 27.11 | 31.60 | 34.49 | 39.32 |
| Total Expenses | - | 38.69 | 44.06 | 48.14 | 54.34 |
| Operating Income | - | 2.97 | 4.01 | 6.58 | 9.66 |
| Total Operating Income As Reported | - | 2.97 | 4.01 | 6.58 | 9.66 |
| EBITDA | - | 3.60 | 4.62 | 7.42 | 10.83 |
| Normalized EBITDA | - | 3.60 | 4.62 | 7.42 | 10.83 |
| EBIT | - | 2.97 | 4.01 | 6.58 | 9.66 |
| Interest Income | - | 0.02 | 0.08 | 0.46 | 0.62 |
| Net Interest Income | - | 0.02 | 0.08 | 0.46 | 0.62 |
| Other Non Operating Income Expenses | -0.01 | - | - | - | - |
| Other Income Expense | -0.01 | - | - | - | - |
| Interest Income Non Operating | - | 0.02 | 0.08 | 0.46 | 0.62 |
| Net Non Operating Interest Income Expense | - | 0.02 | 0.08 | 0.46 | 0.62 |
| Pretax Income | - | 3 | 4.09 | 7.04 | 10.28 |
| Tax Provision | - | 0.69 | 0.92 | 1.89 | 2.75 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | 2.31 | 3.17 | 5.15 | 7.54 |
| Net Income From Continuing And Discontinued Operation | - | 2.31 | 3.17 | 5.15 | 7.54 |
| Net Income From Continuing Operation Net Minority Interest | - | 2.31 | 3.17 | 5.15 | 7.54 |
| Net Income | - | 2.31 | 3.17 | 5.15 | 7.54 |
| Net Income Common Stockholders | - | 2.31 | 3.17 | 5.15 | 7.54 |
| Net Income Including Noncontrolling Interests | - | 2.31 | 3.17 | 5.15 | 7.54 |
| Normalized Income | - | 2.31 | 3.17 | 5.15 | 7.54 |
| Diluted NI Availto Com Stockholders | - | 2.31 | 3.17 | 5.15 | 7.54 |
| Basic Average Shares | - | 8.47 | 8.46 | 8.56 | 8.45 |
| Diluted Average Shares | - | 8.77 | 8.70 | 8.86 | 8.91 |
| Reconciled Depreciation | - | 0.63 | 0.61 | 0.84 | 1.17 |
| Reconciled Cost Of Revenue | - | 10.22 | 11.55 | 12.99 | 14.03 |
| Total Other Finance Cost | -0.04 | - | - | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Electromed, Inc.this co. | ELMD | $304M | 40.34 | 7.04 | 17.4% | 26.66 |
| Organogenesis Holdings Inc. | ORGO | $319M | 8.62 | 1.06 | 12.3% | 3.71 |
| Rocket Pharmaceuticals, Inc. | RCKT | $319M | -1.43 | 1.15 | -80.5% | -1.27 |
| Fennec Pharmaceuticals Inc. | FENC | $318M | -32.67 | 8.97 | -27.5% | -37.76 |
| SIGA Technologies, Inc. | SIGA | $318M |
| - |
| - |
| - |
| - |
| 13.65 |
| 1.60 |
| 11.7% |
| 6.73 |
| DiaMedica Therapeutics Inc. | DMAC | $315M | - | 5.61 | -58.4% | - |
| Carlsmed, Inc. | CARL | $303M | -10.22 | 3.06 | -30.0% | -8.40 |
| Alpha Teknova, Inc. | TKNO | $291M | -16.87 | 4.23 | -25.1% | -30.89 |
| OraSure Technologies, Inc. | OSUR | $287M | -4.18 | 0.84 | -20.2% | -1.74 |
| Peer Median | - | -4.18 | 2.33 | -26.3% | -1.74 | |